Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA warns Sanofi-Aventis over misleading Uroxatral promotion

This article was originally published in Scrip

Executive Summary

The US FDA has warned Sanofi-Aventis that a promotional item known as a tent card for its alpha(1)-blocker Uroxatral (alfuzosin extended-release tablets) is misleading because the front side presents effectiveness claims but omits "any risk information associated with its use". Indication and risk information only appear on the back of the card.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts